Advanced in B-Cell Lymphoma

Sung-hsin M. Kuo

No. 1, Changde St, 
TPQ, TW 
Advanced in B-Cell Lymphoma
No. 1, Changde St, 
TPQ, TW 
OverviewLocationsClinical Research

Overview

Sung-hsin Kuo practices in Taiwan. Kuo is rated as an Advanced expert by MediFind in the treatment of B-Cell Lymphoma. Their top areas of expertise are B-Cell Lymphoma, Gastric Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Mastectomy.

Their clinical research consists of co-authoring 127 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 23 articles in the study of B-Cell Lymphoma.

Locations

No. 1, Changde St, TPQ 10048, Taiwan
Other Locations
No. 7, Chung Shan S. Rd, TPQ, Taiwan
No. 7, Chung Shan South Rd, Zhongzheng Dist, TPQ 10002, Taiwan
No.7, Chung Shan South Road, 100, TPQ, Taiwan
No. 7, Chung Shan S. Rd, 100, TPQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Single Arm，Phase Ib/II Study of the Combination of Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas (PTCL)
A Single Arm，Phase Ib/II Study of the Combination of Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas (PTCL)
Enrollment Status: Terminated
Publish Date: July 08, 2024
Intervention Type: Drug
Study Drug: Lenalidomide+Gemcitabine
Study Phase: Phase 1/Phase 2
A Phase I Study of TS-1 With Concurrent Radiotherapy Followed by Gemcitabine and TS-1 in Metastatic Pancreatic Cancer (SR-GS Study)
A Phase I Study of TS-1 With Concurrent Radiotherapy Followed by Gemcitabine and TS-1 in Metastatic Pancreatic Cancer (SR-GS Study)
Enrollment Status: Terminated
Publish Date: January 18, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 1 Less Clinical Trial

127 Total Publications

Response to comment on "the toxicity of hybrid techniques combining hypofractionated whole breast radiotherapy with concomitant tumor bed boost in patients with breast cancer".
Response to comment on "the toxicity of hybrid techniques combining hypofractionated whole breast radiotherapy with concomitant tumor bed boost in patients with breast cancer".
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: December 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Kuo's expertise for a condition
ConditionClose
      View All 29 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile